Loading
Life sciences · Journal article
Discover Oncology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous malignancy characterized by a lack of effective targeted therapies. Precise prognostic stratification and a deep understanding of the tumor microenvironment are critical to optimizing individualized clinical management and prognostic evaluation. Transcriptomic profiles and clinical data of TNBC patients were obtained from The Cancer Genome Atlas (TCGA) database. Differential expression and functional enrichment analyses were performed between TNBC tumor tissues and histologically normal adjacent breast tissues. A prognostic model was developed using univariable Cox screening and LASSO Cox regression and was externally assessed in GSE58812. Immune and stromal features were evaluated using xCell2, CIBERSORT, ESTIMATE, GSVA, and pathway-level analyses. A five-gene signature comprising SPRR4, P2RX6, ARHGAP6, IVL, and HES2 was associated with overall survival and showed favorable discrimination in TCGA, with lower 36- and 60-month discrimination in GSE58812. Higher risk scores were associated with stromal enrichment and altered immune-cell composition. The five-gene signature was associated with distinct stromal and immune features and may provide complementary prognostic information in TNBC. Further validation in larger, clinically annotated cohorts is required.